Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia VeraHemic and Lymphatic Diseases, Myeloproliferative Disorders, Neoplasms by Site, acquired polycythemia vera, bone marrow disorder, bone marrow neoplasm, hematologic disorder, hematopoietic and lymphoid system neoplasm, neoplasmRecruitingPhase 32026-04-28NCT04116502

4 results · Page 1 of 1

Swipe the table sideways for more columns.

47 results · Page 1 of 2

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
Aberdeen Royal InfirmaryAberdeenUnited Kingdom21
Addenbrooke's HospitalCambridgeUnited Kingdom40
Arrowe Park HospitalMetropolitan Borough of WirralUnited Kingdom3
Belfast City HospitalBelfastUnited Kingdom24
Birmingham Heartlands HospitalBirminghamUnited Kingdom19
Blackpool Victoria HospitalBlackpoolUnited Kingdom15
Calderdale Royal HospitalHalifaxUnited Kingdom5
Castle Hill HospitalCottinghamUnited Kingdom8
Churchill HospitalOxfordUnited Kingdom43
Colchester HospitalColchesterUnited Kingdom2
Freeman HospitalNewcastle upon TyneUnited Kingdom27
Gloucestershire Royal HospitalGloucesterUnited Kingdom6
Good Hope HospitalSutton ColdfieldUnited Kingdom1
Guy's HospitalLondonUnited Kingdom44
Halton HospitalRuncornUnited Kingdom1
Huddersfield Royal InfirmaryHuddersfieldUnited Kingdom8
Kent and Canterbury HospitalCanterburyUnited Kingdom16
Kettering General HospitalKetteringUnited Kingdom5
Leicester Royal InfirmaryLeicesterUnited Kingdom35
New Cross HospitalWolverhamptonUnited Kingdom23
Norfolk and Norwich University HospitalNorwichUnited Kingdom8
North Tyneside General HospitalNorth ShieldsUnited Kingdom4
Northampton General HospitalNorthamptonUnited Kingdom2
Nottingham City HospitalNottinghamUnited Kingdom30
Raigmore HospitalInvernessUnited Kingdom7